{"id":"second-line-systemic-treatment","brandName":"Second-line systemic treatment","genericName":"Second-line systemic treatment","companyId":"instituto-de-investigaci-n-hospital-universitario-la-paz","companyName":"Instituto de Investigación Hospital Universitario La Paz","phase":"marketed","status":"active","modality":"Small molecule","aliases":["Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Instituto de Investigación Hospital Universitario La Paz is exploring second-line systemic treatments across various cancers, including SCLC, biliary tract cancer, and advanced gastric cancer. Key trials are evaluating combinations with radiation therapy and immunotherapy, aiming to improve efficacy and patient outcomes.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a clinical classification describing the treatment sequence in a disease management algorithm, not a specific pharmaceutical agent. Second-line systemic treatments vary widely depending on the disease context (oncology, rheumatology, infectious disease, etc.) and may include chemotherapy, targeted therapy, immunotherapy, or other systemic agents. The specific mechanism depends entirely on which drug is selected as second-line therapy.","oneSentence":"Second-line systemic treatment refers to a category of therapeutic interventions administered after first-line therapy has failed or become unsuitable, rather than a single drug with a defined mechanism.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}